Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax announced the full exercise of the underwriters' option to purchase 960,000 additional ADSs, increasing the total offering size to 7,360,000 ADSs and gross proceeds to approximately $920.0 million. The offering was priced at $125.00 per ADS, a 2.39% premium to the three-day volume-weighted average price, resulting in estimated net proceeds of roughly $874.1 million.
Key figures
- Drug Name
- obefazimod
- Deal Value Usd
- 920000000
- Offering Price
- 125
- Shares Offered
- 7360000
- Net proceeds
- $874.1 million
- Greenshoe shares
- 960000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.